All In Biotech

Drug Trial Radar · NCT07915921

A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer

An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety/Tolerability, Efficacy, and Pharmacokinetic Characteristics of GFH276 in Combination With Chemotherapy (+/- Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II study to explore the safety/tolerability, efficacy, and pharmacokinetic (PK) characteristics of GFH276 in combination with chemotherapy (+/- bevacizumab) or cetuximab in patients with RAS-mutant metastatic colorectal cancer (mCRC).

Conditions

  • CRC

Interventions

  • IrinotecanDrug

    Intravenous irinotecan at a dose of 150 mg/m?

  • OxaliplatinDrug

    Intravenous oxaliplatin at a dose of 85 mg/mr

  • GFH276Drug

    Oral GFH276 administered once daily in combination with other study drugs.

  • Fluorouracil (5-FU)Drug

    Intravenous Fluorouracil at a dose of 2400 mg/m2 via 46-hour infusion.

  • LeucovorinDrug

    Intravenous leucovorin at a dose of 400 mg/m

  • BevacizumabDrug

    at a dose of 5mg/kg

  • Cetuximab (CRC)Drug

    at a dose of500 mg/㎡

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence and severity of AEs and SAEsTime frame: up to 24 months
  2. Phase Ib: The incidence of DLT events: The incidence of DLT eventsTime frame: First 28 days
  3. Phase II: Objective response rate (ORR)Time frame: From first use of medication to disease progression,up to 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.